Publicaciones en las que colabora con Isidoro Martínez González (20)

2023

  1. Corrigendum to “PBMCs gene expression signature of advanced cirrhosis with high risk for clinically significant portal hypertension in HIV/HCV coinfected patients: A cross-control study” [Biomed. Pharmacother. 159 (2023) 114220] (Biomedicine & Pharmacotherapy (2023) 159, (S0753332223000082), (10.1016/j.biopha.2023.114220))

    Biomedicine and Pharmacotherapy

  2. Diagnostic Performance of the HCV Core Antigen Test To Identify Hepatitis C in HIV-Infected Patients: a Systematic Review and Meta-Analysis

    Journal of clinical microbiology, Vol. 61, Núm. 1, pp. e0133122

  3. Diagnostic performance of hepatitis C core antigen assay to identify active infections: A systematic review and meta-analysis

    Reviews in Medical Virology, Vol. 33, Núm. 3

  4. IL7RA rs10491434 polymorphism is related to spontaneous HIV infection control in naïve HIV-infected patients: A retrospective study

    Journal of Medical Virology, Vol. 95, Núm. 11

  5. IRF5-TNOP3 polymorphisms are associated with elite control of HIV infection: A retrospective study

    Journal of medical virology, Vol. 95, Núm. 6, pp. e28841

  6. PBMCs gene expression signature of advanced cirrhosis with high risk for clinically significant portal hypertension in HIV/HCV coinfected patients: A cross-control study

    Biomedicine and Pharmacotherapy, Vol. 159

  7. TNFAIP3-interacting protein 1 polymorphisms and their association with symptomatic human respiratory syncytial virus infection and bronchiolitis in infants younger than one year from South Africa: A case-control study

    International Journal of Infectious Diseases, Vol. 136, pp. 107-110

2022

  1. Meta-analysis: diagnostic accuracy of hepatitis C core antigen detection during therapy with direct-acting antivirals

    Alimentary Pharmacology and Therapeutics, Vol. 56, Núm. 8, pp. 1224-1234

  2. Metabolic Profiling at COVID-19 Onset Shows Disease Severity and Sex-Specific Dysregulation

    Frontiers in Immunology, Vol. 13

  3. Metabolomic changes after DAAs therapy are related to the improvement of cirrhosis and inflammation in HIV/HCV-coinfected patients

    Biomedicine and Pharmacotherapy, Vol. 147

  4. Similar humoral immune responses against the SARS-CoV-2 spike protein in HIV and non-HIV individuals after COVID-19

    Journal of Infection

2021

  1. HCV Cure With Direct-Acting Antivirals Improves Liver and Immunological Markers in HIV/HCV-Coinfected Patients

    Frontiers in Immunology, Vol. 12

  2. HCV eradication with IFN-based therapy does not completely restore gene expression in PBMCs from HIV/HCV-coinfected patients

    Journal of Biomedical Science, Vol. 28, Núm. 1

  3. TRPM5 rs886277 polymorphism predicts hepatic fibrosis progression in non-cirrhotic HCV-infected patients

    Journal of Clinical Medicine, Vol. 10, Núm. 3, pp. 1-10

2020

  1. Near normalization of peripheral blood markers in HIV-infected patients on long-term suppressive antiretroviral therapy: a case-control study

    AIDS (London, England), Vol. 34, Núm. 13, pp. 1891-1897

2019

  1. Genetic variants upstream of TNFAIP3 in the 6q23 region are associated with liver disease severity in HIV/HCV-coinfected patients: A cross-sectional study

    Infection, Genetics and Evolution, Vol. 67, pp. 112-120

  2. Impact of darc rs12075 variants on liver fibrosis progression in patients with chronic hepatitis c: A retrospective study

    Biomolecules, Vol. 9, Núm. 4

  3. TNFAIP3, TNIP1, and MyD88 polymorphisms predict septic-shock-related death in patients who underwent major surgery

    Journal of Clinical Medicine, Vol. 8, Núm. 3

2018

  1. Vitamin D in human immunodeficiency virus infection: Influence on immunity and disease

    Frontiers in Immunology

2016

  1. Relationship of TRIM5 and TRIM22 polymorphisms with liver disease and HCV clearance after antiviral therapy in HIV/HCV coinfected patients

    Journal of Translational Medicine, Vol. 14, Núm. 1